Advances in the Management of Melanoma

被引：1
作者：
Friedlander P. [1 ]
机构：
[1] Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, 10 E 102nd Street, Box 1128, New York, 10029, NY
来源：
Current Dermatology Reports | 2017年 / 6卷 / 4期
关键词：
BRAF; CTLA-4; Immunotherapy; Melanoma; PD-1;
D O I：
10.1007/s13671-017-0202-9
中图分类号：
学科分类号：
摘要：
Purpose of Review: Stage IV melanoma is an aggressive malignancy with the median survival historically being less than 1 year. Approximately 50% of melanomas contain an activating mutation in a targetable component of the mitogen-activated protein kinase (MAPK) pathway called BRAF. Melanoma growth is modulated by activating and inhibitory immune checkpoints. Advances in the management of distantly metastatic and stage III melanoma are reviewed. Recent Findings: Targeting BRAF signaling in patients with metastatic V600 BRAF mutated melanoma and modulation of immune checkpoints confer survival benefit to patients with distantly metastatic melanoma. CTLA-4 blockade confers survival benefit as adjuvant therapy in patients with stage III melanoma. Summary: The efficacy of systemic therapy to treat stage IV melanoma is improving. Advances are being made to improve efficacy of adjuvant therapy for high-risk stage III melanoma patients and to determine optimal surgical management of patients with sentinel lymph node-positive melanoma. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码：288 / 296
页数：8
相关论文
共 52 条
  • [1] Siegel R., Et al., Cancer statistics, 2014, CA Cancer J Clin, 64, 1, pp. 9-29, (2014)
  • [2] Balch C.M., Et al., Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 27, 36, pp. 6199-6206, (2009)
  • [3] Berger A.C., Et al., Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients, Curr Med Res Opin, 32, 9, pp. 1599-1604, (2016)
  • [4] Curtin J.A., Et al., Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, 24, 26, pp. 4340-4346, (2006)
  • [5] Solus J.F., Kraft S., Ras, Raf, and MAP kinase in melanoma, Adv Anat Pathol, 20, 4, pp. 217-226, (2013)
  • [6] Wan P.T., Et al., Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 6, pp. 855-867, (2004)
  • [7] Chapman P.B., Et al., Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma, J Clin Oncol, 17, 9, pp. 2745-2751, (1999)
  • [8] Atkins M.B., Et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993, J Clin Oncol, 17, 7, pp. 2105-2116, (1999)
  • [9] Sondergaard J.N., Et al., Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032, J Transl Med, 8, (2010)
  • [10] Tsai J., Et al., Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc Natl Acad Sci U S A, 105, 8, pp. 3041-3046, (2008)
123456